Adial Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
61.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.56next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Clinical Trial Initiation for AT177 QuarterlyTarget: Phase 1 clinical study initiation in mid-2027
Cash and Cash Equivalents Quarterly4.6MTarget: Sufficient to fund operations into the second half of 2026 (pre-PIPE closing)
PIPE Financing Tranches Closed Annually32M
Watch Items
- Phase 1 Clinical Trial Initiation for AT177Trigger: Mid-2027 target dateAction: Unlocks the second $32 million tranche of the PIPE financing.
- FDA Regulatory Feedback on AD04Trigger: Single pivotal Phase 3 trial alignmentAction: Finalize clinical trial design and protocol for the planned Phase 3 program of AD04 in Alcohol Use Disorder.
- Stockholder Approval for Azora Transaction Share IssuanceTrigger: Stockholder vote dateAction: Obtain approval to convert Series A non-voting convertible preferred stock and fully implement the post-merger capital structure.
Research as of 20 Jun 2026